Research programme: anticancer monoclonal antibodies - A&G Pharmaceutical

Drug Profile

Research programme: anticancer monoclonal antibodies - A&G Pharmaceutical

Alternative Names: Anti-GP88 monoclonal antibody; Anti-PCDGF monoclonal antibody; Anti-PCDGF-GP88 monoclonal antibody; Anti-PCDGF/GP88 monoclonal antibody; Anti-progranulin monoclonal antibody; CT P4; PC-cell-derived growth factor - A&G Pharmaceutical

Latest Information Update: 16 Mar 2016

Price : $50

At a glance

  • Originator A&G Pharmaceutical
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Intercellular signalling peptide and protein inhibitors; PC cell-derived growth factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Lung cancer

Most Recent Events

  • 16 Mar 2016 Preclinical development is ongoing for Breast cancer and Lung cancer in the US (Celltrion pipeline, March 2016)
  • 01 Oct 2015 Preclinical development is ongoing in USA
  • 28 Sep 2010 A&G Pharmaceutical receives SBIR grant from the National Cancer Institute for anticancer monoclonal antibodies development in Breast and Lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top